These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 18195670)
1. Treating multiple sclerosis in the natalizumab era: risks, benefits, clinical decision making, and a comparison between North American and European Union practices. Giovannoni G; Kinkel P; Vartanian T Rev Neurol Dis; 2007; 4(4):184-93. PubMed ID: 18195670 [TBL] [Abstract][Full Text] [Related]
3. [Natalizumab in the treatment of multiple sclerosis]. Horga A; Horga de la Parte JF Rev Neurol; 2007 Sep 1-15; 45(5):293-303. PubMed ID: 17876741 [TBL] [Abstract][Full Text] [Related]
4. Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis. Foley J Am J Manag Care; 2010 Jun; 16(6 Suppl):S178-83. PubMed ID: 20615054 [TBL] [Abstract][Full Text] [Related]
5. Safety profile of Tysabri: international risk management plan. Iaffaldano P; D'Onghia M; Trojano M Neurol Sci; 2009 Oct; 30 Suppl 2():S159-62. PubMed ID: 19882366 [TBL] [Abstract][Full Text] [Related]
9. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Goodin DS; Cohen BA; O'Connor P; Kappos L; Stevens JC; Neurology; 2008 Sep; 71(10):766-73. PubMed ID: 18765653 [TBL] [Abstract][Full Text] [Related]
10. Natalizumab for the treatment of multiple sclerosis and Crohn's disease. Keeley KA; Rivey MP; Allington DR Ann Pharmacother; 2005 Nov; 39(11):1833-43. PubMed ID: 16219898 [TBL] [Abstract][Full Text] [Related]
13. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease. Ko HH; Bressler B Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431 [TBL] [Abstract][Full Text] [Related]